Papers authored by Swillo RE

Collect these papers and discover other ones on Labmeeting. Learn more.
GAP-134 ([2S,4R]-1-[2-Aminoacetyl]4-Benzamidopyrrolidine-2-Carboxylic Acid) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs.
+ cite this
+ View Abstract
Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, Petersen JS, Gardell SJ, and Vlasuk GP
Journal of cardiovascular pharmacology and therapeutics 14(3):207-14, 2009 Sep - Who cited this? | PubMed ID: 19721133 | Fulltext
Recommend
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
+ cite this
+ View Abstract
Piatnitski Chekler EL, Butera JA, Di L, Swillo RE, Morgan GA, Rossman EI, Huselton C, Larsen BD, and Hennan JK
Bioorganic & medicinal chemistry letters 19(16):4551-4, 2009 Aug 15 - Who cited this? | PubMed ID: 19616941 | Fulltext
Recommend
The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model.
+ cite this
+ View Abstract
Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, and Hennan JK
The Journal of pharmacology and experimental therapeutics 329(3):1127-33, 2009 Jun - Who cited this? | PubMed ID: 19252062 | Fulltext
Recommend
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.
+ cite this
+ View Abstract
Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, and Petersen JS
Journal of medicinal chemistry 52(4):908-11, 2009 Feb 26 - Who cited this? | PubMed ID: 19175320 | Fulltext
Recommend
Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis.
+ cite this
+ View Abstract
Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, and Crandall DL
Journal of thrombosis and haemostasis : JTH 6(9):1558-64, 2008 Sep - Who cited this? | PubMed ID: 18624980 | Fulltext
Recommend
Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.
+ cite this
+ View Abstract
Hennan JK, Swillo RE, Morgan GA, Keith JC, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, and Crandall DL
The Journal of pharmacology and experimental therapeutics 317(1):236, 2006 Apr - Who cited this? | PubMed ID: 16344331 | Fulltext
Recommend
Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
+ cite this
+ View Abstract
Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, and Vlasuk GP
Thrombosis and haemostasis 95(3):469-75, 2006 Mar - Who cited this? | PubMed ID: 16525575 | Fulltext
Recommend
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
+ cite this
+ View Abstract
Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, and Crandall DL
The Journal of pharmacology and experimental therapeutics 314(2):710-6, 2005 Aug - Who cited this? | PubMed ID: 15860572 | Fulltext
Recommend
WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.
+ cite this
+ View Abstract
Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, and Swillo RE
Biochemical and biophysical research communications 311(4):904-8, 2003 Nov 28 - Who cited this? | PubMed ID: 14623266 | Fulltext
Recommend
Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia.
+ cite this
+ View Abstract
Friedrichs GS, Swillo RE, Jow B, Bridal T, Numann R, Warner LM, Killar LM, and Sidek K
Journal of cardiovascular pharmacology 39(1):18-28, 2002 Jan - Who cited this? | PubMed ID: 11743224 | Fulltext
Recommend
Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.
+ cite this
+ View Abstract
Gomoll AW, Roth RA, Swillo RE, Baird AJ, Sargent CS, Behling RW, Malone HJ, and Grover GJ
The Journal of pharmacology and experimental therapeutics 281(1):24-33, 1997 Apr - Who cited this? | PubMed ID: 9103476 | Fulltext
Recommend



Search Google Scholar for Swillo RE

Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab
Sign Up

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.


Sponsored Product



Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!